# Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

> **NCT05870475** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 94 (estimated)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Pegylated interferon α-2b

## Key facts

- **NCT ID:** NCT05870475
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-30
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870475, "Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05870475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*